Galderma's Injectable Empire: Beauty's Wild West?

Galderma, a leading Swiss injectables maker, has seen its sales rise significantly, reaching $2.5bn in 2025, fueled by the normalization of aesthetic treatments. The company offers products like botulinum toxin and fillers, contributing to a booming market where clinics are becoming commonplace.

Despite surging demand, the industry faces risks due to a lack of control over who administers treatments. The aesthetics field is described as a "wild west" with a rapid influx of untrained practitioners. In the UK, for example, the number of professionals administering Botox increased by 437% in two years.

Galderma is actively training over 100,000 healthcare professionals annually to address these safety concerns and minimize adverse outcomes. The company, which was co-founded by L'Oréal and Nestlé and later floated on the stock exchange, now holds a market capitalization of approximately $50bn.

Concerns also extend to emerging trends like "baby Botox," where young individuals seek preventative treatments. This trend, along with the broader demand for cosmetic procedures, is partly driven by extensive social media advertising. Galderma emphasizes its role in promoting a "natural look" and distancing itself from extreme aesthetic results.